Therapy of penicillin-resistant pneumococcal meningitis

Schwartz, Mary T.; Tunkel, Allan R.

doi:10.1016/s0934-8840(11)80790-5

Cited by 2 publications

(1 citation statement)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The introduction of penicillin diminished interest in pneumococcal vaccination, and nearly two decades passed before the need for pneumococcal vaccines was accepted and led to a new initiative to develop pneumococcal polysaccharide vaccines in the late 1960s (22,80). As we approach the 21st century, we are again faced with a crisis in therapy of pneumococcal infections because of the rise of antibiotic resistance of S. pneumoniae (229,245,275) and the emergence of hosts with impaired immunity.…”

Section: Polyvalent Pneumococcal Polysaccharide Vaccinesmentioning

confidence: 99%

Use of Licensed Vaccines for Active Immunization of the Immunocompromised Host

1998

View full text Add to dashboard Cite

SUMMARY The latter part of the 20th century has witnessed an unprecedented rise in the number of individuals with impaired immunity. This is primarily attributable to the increased development and use of antineoplastic therapy for malignancies, organ and bone marrow transplantation, and the AIDS epidemic. Individuals with impaired immunity are often at increased risk for infections, and they can experience more severe and complicated courses of infection. The lack of therapy for a variety of viruses and the rise in antimicrobial resistance of many pathogens have focused attention on vaccination to prevent infectious diseases. The efficacy of most licensed vaccines has been established in immunocompetent hosts. However, there is also considerable experience with most vaccines in those with impaired immunity. We reviewed the use of licensed live, inactivated, and polysaccharide vaccines in this group, and several themes emerged: (i) most vaccines are less immunogenic in those with impaired immunity than in normal individuals; (ii) live vaccines are generally contraindicated in this group; and (iii) the efficacy of many commonly used vaccines has not been established in people with impaired immunity. This review suggests that for most vaccines there are little or no efficacy data in those with impaired immunity but their use in this patient group is generally safe.

show abstract